comparemela.com

Latest Breaking News On - Cetrorelix acetate - Page 1 : comparemela.com

Specialty Generics Market Set for Robust Growth with an 8.7% CAGR Through 2032

Specialty Generics Market Set for Robust Growth with an 8.7% CAGR Through 2032
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Brazil
India
Indonesia
Russia
United-arab-emirates
Nigeria
Algeria
Egypt
South-korea
South-africa
Vietnam
Republic-of

Gland Pharma Shares Rise 4% After Firm Recieves USFDA Nod For Cancer Treatment Injection

Gland Pharma shares gained four per cent in trade on May 7, after the pharma major received the US FDA's nod for Plerixafor injection

Mitsubishi-tanabe-pharma-corporation
Gland-pharma
Sanofi-india
Cetrorelix-acetate
Mitsubishi-tanabe-pharma
Land-pharma-cancer-injection
Gland-pharma-shares

Gland Pharma gets FDA nod for Cetrorelix Acetate for injection but stock down

Gland Pharma expects to launch the product in the near-term through its marketing partner

United-states
Drug-administration
Serono-inc
United-states-food
Cetrorelix-acetate
Gland-pharma
Gland-pharma-share-price-today

United States Specialty Injectable Generics (Drugs,

Dublin, Nov. 28, 2023 (GLOBE NEWSWIRE) The

California
United-states
Dublin
Ireland
American
Amneal-pharmaceuticals-inc
Baxter-international
Sagent-pharmaceuticals-inc
Application-movement-analysis
Teva-pharmaceutical-industries-ltd
Company-profiles-listing

Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM

/PRNewswire/ Akorn Operating Company LLC, a specialty pharmaceutical company, is launching the first to market generic Cetrorelix Acetate for Injection 0.25.

Germany
California
United-states
Anaheim
American
Serono-cetrotide
Douglas-boothe
American-society-for-reproductive-medicine-conference
Akorn-operating-company
Reproductive-technology
Akorn-inc
Merck-kga

vimarsana © 2020. All Rights Reserved.